Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Phase 1a/b study of monoclonal antibody CAEL-101 (11-1F4) in patients with AL amyloidosis

Camille Vanessa Edwards, Nisha Rao, Divaya Bhutani, Markus Mapara, Jai Radhakrishnan, Sofia Shames, Mathew S. Maurer, Siyang Leng, Alan Solomon, Suzanne Lentzsch, Andrew Eisenberger

Blood (2021) 138 (25): 2632–2641.

https://doi.org/10.1182/blood.2020009039

Published: 2021

Includes: Supplemental data

Journal Articles

Personalizing Amyloidosis Therapy with Real Time PET Imaging of Fibril-Reactive Monoclonal Antibody Cael-101

Jing Fu, PhD, Alan Solomon, MD, Patrick Carberry, PhD, John Castrillon, Jongho Kim, MD PhD, Suzanne Lentzsch, MD PhD, Akiva Mintz, MD PhD

Blood (2018) 132 (Supplement 1): 1003.

https://doi.org/10.1182/blood-2018-99-118177

Published: 2018

Journal Articles

Final Analysis of the Phase 1a/b Study of Chimeric Fibril-Reactive Monoclonal Antibody 11-1F4 in Patients with Relapsed or Refractory AL Amyloidosis

Camille Vanessa Edwards, MBBS, BSc, Julia Gould, BA, Arielle L Langer, MD MPH, Markus Y Mapara, MD PhD, Jai Radhakrishnan, MD, Mathew S. Maurer, MD, Shahzad Raza, MD, John G. Mears, MD, Siyang Leng, MD, Jonathan S. Wall, PhD, Andrew Eisenberger, MD, Alan Solomon, MD, Suzanne Lentzsch, MD PhD

Blood (2017) 130 (Supplement 1): 509.

https://doi.org/10.1182/blood.V130.Suppl_1.509.509

Published: 2017

Journal Articles

Analysis of the Phase 1a/b Study of Chimeric Fibril-Reactive Monoclonal Antibody 11-1F4 in Patients with AL Amyloidosis

Camille V Edwards, MD, Julia Gould, BA, Arielle L Langer, MD MPH, Markus Mapara, MD PhD, Jai Radhakrishnan, MD, Matthew S Maurer, MD, Shahzad Raza, MD, John G Mears, MD, Jonathan S Wall, PhD, Alan Solomon, MD, Suzanne Lentzsch, MD PhD

Blood (2016) 128 (22): 643.

https://doi.org/10.1182/blood.V128.22.643.643

Published: 2016

Journal Articles

Results of Phase I Study of Chimeric Fibril-Reactive Monoclonal Antibody 11-1F4 in Patients with AL Amyloidosis

Arielle L Langer, MD MPH, Susanna Miao, Markus Mapara, MD PhD, Jai Radhakrishnan, MD, Mathew S. Maurer, MD, Shahzad Raza, MD, John G. Mears, MD, Alan Solomon, MD, Suzanne Lentzsch, MD PhD

Blood (2015) 126 (23): 188.

https://doi.org/10.1182/blood.V126.23.188.188

Published: 2015

Journal Articles

Radioimmunodetection of amyloid deposits in patients with AL amyloidosis

Jonathan S. Wall, Stephen J. Kennel, Alan C. Stuckey, Misty J. Long, David W. Townsend, Gary T. Smith, Karen J. Wells, Yitong Fu, Michael G. Stabin, Deborah T. Weiss, Alan Solomon

Blood (2010) 116 (13): 2241–2244.

https://doi.org/10.1182/blood-2010-03-273797

Published: 2010

Journal Articles

Knockdown of Pathologic Immuoglobulin Light Chain Protein by Small Interfering RNA Molecules.

Jonathan E Phipps, BSc, MSc, James S Foster, BSc, MSc, Daniel P Kestler, PhD, Robert Donnell, DVM, PhD, Alan Solomon, MD, Jonathan S Wall, BS, PhD

Blood (2009) 114 (22): 4407.

https://doi.org/10.1182/blood.V114.22.4407.4407

Published: 2009

Journal Articles

Splenic plasma cells can serve as a source of amyloidogenic light chains

Alan Solomon, Sallie D. Macy, Craig Wooliver, Deborah T. Weiss, Per Westermark

Blood (2009) 113 (7): 1501–1503.

https://doi.org/10.1182/blood-2008-04-154484

Published: 2009

Journal Articles

Misclassification of amyloidosis is unwarranted

Alan Solomon, Charles L. Murphy, Per Westermark

Blood (2006) 108 (2): 776–777.

https://doi.org/10.1182/blood-2006-02-005462

Published: 2006

Journal Articles

Clinical efficacy of high-dose dexamethasone with maintenance dexamethasone/alpha interferon in patients with primary systemic amyloidosis: results of United States Intergroup Trial Southwest Oncology Group (SWOG) S9628

Madhav V. Dhodapkar, Mohamad A. Hussein, Erik Rasmussen, Alan Solomon, Richard A. Larson, John J. Crowley, Bart Barlogie

Blood (2004) 104 (12): 3520–3526.

https://doi.org/10.1182/blood-2004-05-1924

Published: 2004

Journal Articles

Definition of Organ Involvement and Treatment Response in Primary Systemic Amyloidosis (AL): A Consensus Opinion from the 10th International Symposium on Amyloid and Amyloidosis.

Morie Abraham Gertz, M.D., Raymond Comenzo, M.D., Rodney H. Falk, M.D., Jean-Paul Fermand, M.D., Bouke P. Hazenberg, M.D., Philip N. Hawkins, M.D., Giampaolo Merlini, M.D., Philippe Moreau, M.D., Pierre Ronco, M.D., Vaishali Sanchorawala, M.D., Orhan Sezer, M.D., Alan Solomon, M.D., Giles Grateau, M.D.

Blood (2004) 104 (11): 754.

https://doi.org/10.1182/blood.V104.11.754.754

Published: 2004

Journal Articles

A molecular basis for nonsecretory myeloma

Daniel Coriu, Kristal Weaver, Maria Schell, Manfred Eulitz, Charles L. Murphy, Deborah T. Weiss, Alan Solomon

Blood (2004) 104 (3): 829–831.

https://doi.org/10.1182/blood-2004-02-0477

Published: 2004

Journal Articles

Do V L genes have prognostic relevance?

Alan Solomon

Blood (2003) 101 (10): 3759.

https://doi.org/10.1182/blood-2003-03-0683

Published: 2003

Journal Articles

Transient Monoclonal Gammopathy Associated With Cytomegalovirus Infection

Helen Vodopick, Dr., Stuart J. Chaskes, Alan Solomon, John A. Stewart

Blood (1974) 44 (2): 189–195.

https://doi.org/10.1182/blood.V44.2.189.189

Published: 1974

Journal Articles

Myeloma Proteins, Bence Jones Proteins and Normal Immunoglobulins in Multiple Myeloma

VINCENT CAGGIANO, M.D., JANET CUTTNER, M.D., ALAN SOLOMON, M.D.

Blood (1967) 30 (3): 265–287.

https://doi.org/10.1182/blood.V30.3.265.265

Published: 1967

Journal Articles

Immunohistologic Localization of Gamma-1-Macroglobulins, Beta-2A-Myeloma Proteins, 6.6 S Gamma-Myeloma Proteins and Bence Jones Proteins

ALAN SOLOMON, M.D., JOHN L. FAHEY, M.D., RICHARD A. MALMGREN, M.D.

Blood (1963) 21 (4): 403–423.

https://doi.org/10.1182/blood.V21.4.403.403

Published: 1963

NARROW

Phase 1a/b study of monoclonal antibody CAEL-101 (11-1F4) in patients with AL amyloidosis

Personalizing Amyloidosis Therapy with Real Time PET Imaging of Fibril-Reactive Monoclonal Antibody Cael-101

Final Analysis of the Phase 1a/b Study of Chimeric Fibril-Reactive Monoclonal Antibody 11-1F4 in Patients with Relapsed or Refractory AL Amyloidosis

Analysis of the Phase 1a/b Study of Chimeric Fibril-Reactive Monoclonal Antibody 11-1F4 in Patients with AL Amyloidosis

Results of Phase I Study of Chimeric Fibril-Reactive Monoclonal Antibody 11-1F4 in Patients with AL Amyloidosis

Radioimmunodetection of amyloid deposits in patients with AL amyloidosis

Knockdown of Pathologic Immuoglobulin Light Chain Protein by Small Interfering RNA Molecules.

Splenic plasma cells can serve as a source of amyloidogenic light chains

Misclassification of amyloidosis is unwarranted

Clinical efficacy of high-dose dexamethasone with maintenance dexamethasone/alpha interferon in patients with primary systemic amyloidosis: results of United States Intergroup Trial Southwest Oncology Group (SWOG) S9628

Definition of Organ Involvement and Treatment Response in Primary Systemic Amyloidosis (AL): A Consensus Opinion from the 10th International Symposium on Amyloid and Amyloidosis.

A molecular basis for nonsecretory myeloma

Do V L genes have prognostic relevance?

Transient Monoclonal Gammopathy Associated With Cytomegalovirus Infection

Myeloma Proteins, Bence Jones Proteins and Normal Immunoglobulins in Multiple Myeloma

Immunohistologic Localization of Gamma-1-Macroglobulins, Beta-2A-Myeloma Proteins, 6.6 S Gamma-Myeloma Proteins and Bence Jones Proteins

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only